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Uliginosin BPrevious studies have shown that uliginosin B inhibits dopamine reuptake in rat brain. This compound occurs in
Hypericum polyanthemum and H. caprifoliatum for which was reported to have antinociceptive effect sensitive to
naloxone. The aimof this studywas to assess the antinociceptive effect of uliginosin B and to evaluate the involve-
ment of opioid and dopaminergic receptors activation. Uliginosin B presented antinociceptive effect in hot-plate
and abdominal writhing tests, in mice, at doses that did not impair the motor coordination (15 mg/kg, i.p.).
Uliginosin B in high dose (90 mg/kg, i.p.) presented ataxic effect in the rotarod apparatus. These effects seem to
be mediated by distinct receptors since the effect on the hot-plate was completely abolished by naloxone and
sulpiride, but it was unaffected by SCH 23390. On the other hand, the motor impairment induced by uliginosin
B was completely prevented by naloxone and partially prevented by sulpiride and SCH 23390. However, the
receptors' activation appears to be indirect since uliginosin B did not bind to opioid and dopaminergic receptors.
Thus, uliginosin B effects probably are due to its ability to inhibitmonoamine reuptakewith consequent activation
of dopamine receptors and indirect stimulation of opioid system.
© 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Phloroglucinol derivatives are molecules present in several plant
species, e.g. Hypericum perforatum, Humulus lupulus and some species
of Elaphoglossum genus. This group of substances displays biological
activities such as antimicrobial (Jayasuriya et al., 1991; Rocha et al.,
1995; Saddiqe et al., 2010), anxiolytic (Zanoli et al., 2005), antide-
pressant (Linde et al., 2008; Viana et al., 2005) and antinociceptive
(Abdel-Salam, 2005; Galeotti et al., 2010). Clinical trials showed that
phloroglucinols reduce pain in irritable bowel (Cargill et al., 1992;resonance; 1H RMN, proton
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burning mouth syndromes (Sardella et al., 2008).
Hyperforin is one of the most known phloroglucinol derivative; it
occurs in H. perforatum, a European species with clinical antidepressant
effect (Linde et al., 2008). Hyperforin inhibits monoamines (Muller
et al., 2001), glutamate and GABA (gamma-aminobutyric acid) reup-
take (Wonnemann et al., 2000) with similar efﬁcacy (Gobbi et al.,
2001; Müller, 2003) without interacting directly with their neuronal
transporters (Singer et al., 1999); changes membrane ﬂuidity (Eckert
et al., 2004); inﬂuences cell functions by blocking calcium (Fisunov
et al., 2000), sodium and potassium ions voltage-gated channels
(Chatterjee et al., 1999). This compound also acts on ligand-gated chan-
nels, such as TRPC6 (canonical transient receptor potential 6) (Tu et al.,
2010) and NMDA (N-methyl-D-aspartic acid) receptors (Kumar et al.,
2006). Recently, authors have demonstrated that hyperforin presents
thermal antinociception mediated by opioid system (Galeotti et al.,
2010).
Research carried out by our group has shown that uliginosin B
(Fig. 1), a phloroglucinol derivative from Hypericum species native to
Rio Grande do Sul, Brazil, such as H. caprifoliatum (Nor et al., 2008),
H. myrianthum (Ferraz et al., 2002), H. polyanthemum and H. carinatum
(Nor et al., 2004), inhibits monoamines synaptosomal reuptake in rat
brain, especially dopamine without binding to its neuronal carriers
(Stein et al., 2012). This compound presents a dimeric structure con-
sisting of ﬁlicinic acid and phloroglucinol moieties (Ferraz et al., 2002;
Fig. 1. Chemical structure of uliginosin B isolated from Brazilian Hypericum species.
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taxonomic marker for species of Hypericum native to South Brazil
(Nor et al., 2004) and differs from hyperforin and ad-hyperforin,
which possess a bicyclononane skeleton substituted with several iso-
prene chains.
Other compounds isolated from South Brazilian Hypericum species
presented biological activities linked to dopaminergic and opioid
modulation: the benzopyran HP1 (6-isobutyryl-5,7-dimethoxy-2,2-
dimethyl-benzopyran) exhibited antinociceptive effect that was
blocked by naloxone (Haas et al., 2010); the ﬂavonoid hyperoside
demonstrated antidepressant-like activity in rodents that seems to
be underlain by dopaminergic neurotransmission (Haas et al., 2011).
In this study we have assessed uliginosin B antinociceptive effect on
hot-plate andwrithing tests inmice. The possible involvement of opioid
system and dopaminergic neurotransmission was also investigated
by evaluating the inﬂuence of antagonists (naloxone, SCH 23390 and
sulpiride) on the antinociceptive effect of uliginosin B in the hot-plate
and rotarod tests as well as by using binding assays to dopaminergic
and opioid receptors.
2. Materials and methods
2.1. Plant material
Aerial parts of H. myriathum Cham. & Schltdl. were collected in
Paraíso do Sul (29 44 10 S; 53 09 48W), Rio Grande do Sul state, Brazil,
in February 2009. The plant was identiﬁed by Ph.D. Sérgio Bordignon
(UNILASALLE-RS-BRAZIL) and the voucher was deposited in the her-
barium of the Universidade Federal do Rio Grande do Sul — ICN
H. myrianthum, Bordignon - 1402. Plant collection was authorized by
Conselho de Gestão do Patrimônio Genético — CGEN – and Instituto
Brasileiro do Meio Ambiente — IBAMA – 003/2008 P 02000.001717/
2008‐60.
2.2. Uliginosin B extraction and isolation procedures
Dried and powdered aerial parts of H. myrianthum were extracted
with n-hexane bymaceration (3×24 h at 20 °C). The combined extracts
were evaporated to dryness under reduced pressure and submitted to
silica gel column chromatography G60 (Merck®) (50 cm×3 cm) using
n-hexane:dichloromethane gradient system as the mobile phase. The
uliginosin B enriched fraction obtained was puriﬁed by preparative
TLC performed on 20 cm×20 cm glass-supported plates covered
with 0.5 mm layers of silica gel GF254 (Merck®), with n-hexane:
dichloromethane (1:1 v/v) as chromatographic eluent. Band was
detected using UV light (254 nm) and the purity of uliginosin B was
conﬁrmed by high performance liquid chromatography (HPLC) analysis
(Nunes et al., 2009). The uliginosin B retention timewas comparedwith
standard compound (authentic sample), previously identiﬁed by 1H
and 13C RMN (Rocha et al., 1995, 1996).
2.3. Drugs and treatments
GDP (guanosine diphosphate), GTPγS (guanosine-5′-O-(3-thio)
triphosphate), SCH 23390 (R-(+)-8-chloro-2,3,4,5-tetrahydro-3-
methyl-5-phenyl-1H-3-benzazepine-7-ol) and haloperidol by Sigma‐Aldrich Co.; [3H]-naloxone, [3H]-SCH 23390 and [3H]-sulpiride by
Amersham, Orsay, France; naloxone–Narcan® and morphine–Dimorf®
by Cristalia, São Paulo, Brazil; sulpiride by DEG, São Paulo, Brazil;
acetic acid, n-hexane, dichloromethane and polysorbate 80 by Merck,
Darmstadt, Germany; Tri-Carb 2100TR by Packard BioScience Co.;
Ultima Gold and [35S]-GTPγS by Perkin Elmer, Courtaboeuf, France;
dipyrone–Novalgina® by Sanoﬁ-Aventis, São Paulo, Brazil; codeine–
Tylex® by Janssen-Cilag, São José dos Campos, Brazil.
Uliginosin B was suspended in saline with an additional 2% poly-
sorbate 80 immediately before using. Considering that drugs absorp-
tion rate is dependent on the anatomical site from which absorption
takes place, uliginosin B was administered by oral (gavage) or intra-
peritoneal route 60 and 30 min before behavioral testing, respective-
ly. The doses were chosen based on previous results published by our
group (Stein et al., 2012). All treatmentswere administered at 10 mL/kg
body weight.
2.4. Behavioral experiments
2.4.1. Animals
Adult male CF1 mice (25–35 g) purchased from Fundação Estadual
de Produção e Pesquisa em Saúde (FEPPS-RS, Brazil) colony were
used. The animals were housed 8 mice per plastic cages (L: 28 cm, W:
17 cm, H: 13 cm) under a 12 h light/dark cycle (lights on at 7:00 h) at
constant temperature (23±1 °C) with free access to standard certiﬁed
rodent diet (Nuvilab CR-1®) and tap water. All experiments were
approved by a local research ethical committee (UFRGS, number
2008195) and were in compliance with Brazilian law (Brasil, 2008)
and Council for International Organization of Medical Sciences Interna-
tional (CIOMS) guiding principles for biomedical research involving
animals (Bankowski and Howard-Jones, 1985).
2.4.2. Writhing induced by acetic acid
This test was carried out according to Haas et al. (2010) and Viana
et al. (2003). The animals were treated with uliginosin B (15 and
90mg/kg, p.o.), dipyrone (150 mg/kg p.o.) or vehicle (10 mL/kg p.o.)
60 min before receiving an intraperitoneal acetic acid injection (0.8%,
10 mL/kg). Immediately after, mice were then individually placed in
glass observation chambers and observed during 15 min in which the
number of abdominal writhing was counted. The percentage of anti-
nociceptive activity was calculated as follows:
N–N ′ð Þ=N  100;
N represents the average number of writhing of the control group
and N′ the average number of abdominal writhing of the test group.
2.4.3. Hot-plate test
Firstly, mice were habituated to the nonfunctioning hot-plate
apparatus (Ugo Basile) for 1 min. Thirty minutes later the animals
were placed on the functioning hot-plate (55±2 °C) todeterminebase-
line responsiveness. The time elapsed until the animal licked one of its
hind paws or jumped was recorded in seconds (latency time). Mice
that presented a baseline reaction ofmore than20 swere not used. Sub-
sequently, the animals received uliginosin B (15 and 90 mg/kg p.o. or 5,
10, 15 and 90 mg/kg, i.p.),morphine (10 mg/kg, p.o or 4 mg/kg, i.p.) and
vehicle (10 mL/kg, p.o. or i.p.). To assess the involvement of opioid sys-
tem and dopaminergic neurotransmission, animals were treated with
naloxone (non-selective opioid receptor antagonist, 2.5 mg/kg, s.c.),
sulpiride (dopamine D2/D3/D4 receptor antagonist 10 mg/kg, i.p.) or
SCH 23390 (dopamine D1/D5 receptor antagonist, 15 μg/kg, i.p.) 10, 15
or 30 min respectively before receiving uliginosin B (15 or 90 mg/kg,
i.p.) or vehicle. The pretreatmentwas given immediately after the base-
line responsiveness evaluation. Thirty minutes after the intraperitoneal
administration or 60 min after the gavage,micewere placed on the hot-
plate. A maximum latency time of 40 s was imposed.
Table 1
Effect of uliginosin B on abdominal writhing induced by 0.8% acetic acid (10 mL/kg, i.p.)
in mice.
Test samples Dose (p.o.) Number of
writhings±S.D.
Inhibitory ratio compared
to vehicle (%)
Vehicle 10 mL/kg 51.0±7.3 –
Dipyrone 150 mg/kg 7.3±1.6⁎⁎⁎ 85.6%
Uliginosin B 15 mg/kg 5.0±8.3⁎⁎⁎ 90.2%
Uliginosin B 90 mg/kg 2.2±3.7⁎⁎⁎ 95.8%
Data are presented in mean±S.D., n=6 mice/group. Signiﬁcantly different values
were detected by ANOVA one way followed by Student-Newmann–Keuls.
⁎⁎⁎ pb0.001 compared in relation to vehicle.
82 E.D. Stolz et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 39 (2012) 80–872.4.4. Motor coordination test: rotarod
Brieﬂy, the apparatus consisted of a cylinder of 3 cm of diameter
rotating at 5 rpm. One day before testing, the animals were trained
once during 5 min. On the test day, the mice were place in the appa-
ratus again to determine the baseline responsiveness. Only mice
that were able to stay 90 s balanced on the rotarod were selected
for testing. The selected mice received uliginosin B (90 mg/kg, p.o.
or 15 and 90 mg/kg, i.p.), vehicle (10 mL/kg, p.o. or i.p.). Codeine+
acetaminophen (10+166 mg/kg, p.o. or i.p.) were used as an antino-
ciceptive control and haloperidol (4 mg/kg, p.o. or i.p.) was used as an
internal standard. In another set of experiments mice were treated
with naloxone (2.5 mg/kg, s.c.), sulpiride (10 mg/kg, i.p.) or SCH
23390 (15 μg/kg, i.p.) 10, 15 or 30 min, respectively, before receiving
uliginosin B (90 mg/kg, i.p.) or vehicle (10 mL/kg, i.p.). The pre-
treatment was given immediately after the baseline responsive-
ness evaluation. Mice performance was measured 30 min — i.p. or
60 min — p.o. after the drug administration. The integrity of motor
coordination was assessed on the basis of the longest time of perma-
nence and the number of falls in a 5 min period.
2.5. In vitro assays
2.5.1. Animals
Male Sprague‐Dawley rats, weighing 180–200 g, were purchased
from IFFA-CREDO/Charles River Laboratories (Domaine des Oncins,
Saint-Germain sur L'Arbresle, France). They were housed by four in
Makrolon cages (L: 40 cm, W: 25 cm, H: 18 cm), with free access to
water and food (U.A.R., France) and kept in a well ventilated room,
at a temperature of 21±1 °C, under a 12 h light/dark cycle (lights
on between 7:00 h). The procedures used in this study are in compli-
ance with the European Communities Council Directive number 609
(Directive, 1986).
2.5.2. Membrane preparations
Crude membrane preparations were isolated according to the
modiﬁed method described elsewhere (Viana et al., 2005). Non-
treated rats were sacriﬁced by decapitation. Striatum (brain region
enriched in D1 and D2 receptors), thalamus (brain region enriched
in opioid receptors) and forebrain were removed and homogenized
in 20 vol. of 0.32 M sucrose. The homogenates were centrifuged (1 g
for 15 min); the supernatants from two centrifugations were com-
bined and centrifuged (17 g for 30 min). The resulting pellet was
then suspended in Tris buffer (pH 7.4) contained 50 mM Tris/HCl,
100 mM NaCl, 5 mM MgCl2, and 1 mM EDTA for GTPγS binding;
50 mM Tris/HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 1 mM
MgCl2 for dopaminergic receptor binding; 50 mM Tris/HCl, 300 mM
NaCl, and 5 mM KCl for opioid receptor binding, sonicated and
centrifuged (50 g for 10 min). The ﬁnal protein concentration was
determined by the method of Lowry (Lowry et al., 1977). These mem-
branes were freshly used for receptor bindings or GTPγS binding.
2.5.3. Receptor binding assays
In vitro binding assays to opioid and dopaminergic D1 and D2
receptors were performed with membrane from rat forebrain or
striatum, respectively. Brieﬂy, membranes (approx. 200 μg protein)
were incubated in Tris buffer medium containing [3H]-naloxone
for 120 min at 25 °C to opioid receptors, [3H]-SCH 23390 or [3H]-
sulpiride for 60 min at 25 °C to dopaminergic receptors. All incubations
were carried out in presence or absence of different concentrations of
uliginosin B (10−5–10−14M). The ﬁnal volume was 500 μL. Non-
speciﬁc bindingwas determined in presence of naloxone 10 μM(opioid
receptors), SCH 23390 30 μM (D1-like receptors) or sulpiride 300 μM
(D2-like receptors). Incubations were stopped by dilution with 3 mL of
ice-cold incubation medium and immediate ﬁltration through GF/B ﬁl-
ters, previously soaked, for at least 1 h, in 0.5% polyethyleneimine. Each
tube and ﬁlter was rinsed twice with 3 mL of ice-cold incubationmedium. Filters were counted for radioactivity by liquid scintillation
spectrometry in 4 mL of Ultima Gold. Four independent experiments
for each assay were carried out in duplicate.
2.5.4. [35S]-GTPγS binding assay
[35S]-GTPγS binding assays were performed as follows. Thalamus or
striatal membranes (15–20 μg/100 μL) were incubated in the assay
buffer (Tris buffer added with 1 mM dithiothreitol (DTT) and 0.1%
metabisulphite), 10 μM GDP, 0.1 nM [35S]-GTPγS (1250 Ci/mmol) and
in the presence of 10−6–10−10 M uliginosin B, in a total volume of
1 mL. Basal binding was assessed in the absence of opioid peptide ana-
logue and presence of GDP. The non-speciﬁc binding was assessed in
the presence of 10 μM GTPγS. The entire mixture was incubated at
25 °C for 2 h and ﬁltered through Whatman GF/B glass ﬁber ﬁlters,
which had been pre-soaked for 2 h in Tris buffer, and washed three
times with 4 mL of ice-cold Tris buffer. Bound radioactivity was deter-
mined in Tri-Carb 2100TR liquid scintillation counter after overnight
extraction of the ﬁlters in 4 mL of Ultima Gold scintillation ﬂuid. Four
independent experiments for each assay were carried out in duplicate.
Individual dose–response curves were obtained by a non-linear regres-
sion analysis. The percent stimulation of [35S]-GTPγS bindingwas calcu-
lated as followed:
S–Bð Þ=B 100%
S is the stimulated level; B is the basal level of [35S]-GTPγS binding in
the presence of GDP.
2.5.5. Statistical analysis
The data were evaluated using one or two-way RM analysis of
variance – ANOVA – followed by Student-Newman–Keuls test
depending on the experimental design. All results were expressed
in mean±S.E.M. The analyses were performed using Sigma Stat 3.2
software, Jandel Scientiﬁc Corporation. Differences were considered
statistically signiﬁcant at pb0.05.
3. Results
3.1. Antinociceptive effect of uliginosin B by oral and intraperitoneal
route
The effects of the oral administration of uliginosin B 15 and 90 mg/kg
on the abdominal writhing induced by acetic acid are presented in
Table 1. Both doses of uliginosin B inhibited abdominal writhing in
more than 90% in comparison with vehicle group [one-way ANOVA
F (3,23)=93.152; pb0.001], this effect was comparable to dipyrone
150 mg/kg effect (86% inhibition).
Fig. 2 shows the effect of uliginosin B in the mice hot-plate test.
The effect of the oral treatment with uliginosin B 15 and 90 mg/kg are
presented in the Fig. 2A. Two-way RM ANOVA revealed a signiﬁcant
effect of uliginosin B treatment [F (3,65)=3.903, pb0.019], exposition
[F (1,65)=60.181, pb0.001] and treatment×exposition interaction
[F (3,65)=8.360, pb0.001]. Post hoc analysis indicated a signiﬁcant
Fig. 2. Effect of uliginosin B (ULI) and morphine (MOR) on the hot-plate test, adminis-
tered by oral route (panel A) and intraperitoneal route (panel B). Data are presented in
mean±S.E.M. (n=10 mice/group). Signiﬁcantly different values were detected by
ANOVA two way RM followed by Student-Newmann–Keuls: ⁎⁎⁎pb0.001; ⁎pb0.05
compared to vehicle; ###pb0.001, ##pb0.01, #pb0.05 compared to their respective
basal latency (Basal); aaapb0.001, apb0.05 compared to uliginosin B 5 mg/kg, i.p.;
bbpb0.01, bpb0.05 compared to uliginosin B 10 mg/kg, i.p.
Fig. 3. Effect of the uliginosin B (ULI), haloperidol (HAL) and codeine (COD) on the rotarod app
intraperitoneal route (panel C: number of falls; panel D: permanence time). Data are present
ANOVA two way RM followed by Student-Newmann–Keuls: ⁎⁎⁎pb0.001 compared to vehicle
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son with vehicle group at second exposition (named after) (pb0.05)
as well as with its basal responsiveness (ULI 15 mg/kg: pb0.01; ULI
90 mg/kg: pb0.05). Fig. 2B depicts the results from intraperitoneal
treatment with uliginosin B 5, 10, 15 and 90mg/kg in the hot-plate
test. Two-way RM ANOVA showed a signiﬁcant effect of uliginosin
B treatment [F (5,119)=7.526, pb0.001], exposition [F (1,119)=
187.979, pb0.001] and treatment×exposition interaction [F (5,119)=
26.075, pb0.001]. Post hoc analysis indicated a signiﬁcant increase in
the latency time elicited by uliginosin B at doses of 10, 15 and 90 mg/kg
when compared with vehicle group at second exposition (pb0.001) as
well as with its basal responsiveness (ULI 10 mg/kg: pb0.01; ULI 15
and 90 mg/kg: pb0.001). In addition, the latencies of mice that re-
ceived uliginosin B 15 (pb0.01) and 90 mg/kg (pb0.05) were signiﬁ-
cantly higher than the latency of the group treated with uliginosin B
10 mg/kg, characterizing a dose–response relationship.
The effect of uliginosin B on motor performance was evaluated in
the rotarod apparatus (Fig. 3). The oral administration of uliginosin B
90 mg/kg did not alter the rotarod performance (Fig. 3A and B). The
intraperitoneal treatment with uliginosin B 90 mg/kg increased the
number of falls [two-way RM ANOVA: Ftreatment (4,99)=18.263,
pb0.001; Fexposition (1,99)=49.65, pb0.001; Finteraction (4,99)=
17.826, pb0.001] (Fig. 3C) and decreased the permanence time [two-
way RM ANOVA: Ftreatment (4,99)=10.892, pb0.001; Fexposition (1,99)=
50.303, pb0.001; Finteraction (4,99)=15.316, pb0.001] (Fig. 3D) of mice
at the second exposition to rotarod. Uliginosin B 15 mg/kg (i.p.) did not
alter motor performance on rotarod test. Considering these results, the
intraperitoneal treatment with uliginosin B was selected to be used for
investigating antinociceptive and ataxic mechanism action.3.2. Effect of opioid and dopaminergic systems on uliginosin B thermal
antinociception and motor effect
The possible involvement of opioid and dopaminergic systems in the
uliginosin B effectwas evaluated on hot-plate and rotarod tests by using
naloxone, SCH 23390 and sulpiride prior to the intraperitoneal adminis-
tration of uliginosin B. Naloxone, SCH 23390 and sulpiride themselvesaratus, administered oral route (panel A: number of falls; panel B: permanence time) and
ed in mean±S.E.M. (n=10 mice/group). Signiﬁcantly different values were detected by
; ###pb0.001 compared to their respective baseline responsiveness (Basal).
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(Figs. 4 and 5).
The results depicted in Fig. 4 show the effect of the pretreatment
with the antagonists on the antinociceptive effect of uliginosin B 15
and 90 mg/kg (i.p.) in hot-plate test. Two-way RM ANOVA revealed
that pretreatment with naloxone (2.5 mg/kg, s.c.) blocked the anti-
nociceptive effect of uliginosin B 15 mg/kg (i.p.) only [two-way RM
ANOVA: Ftreatment (5,119)=4.641, pb0.001; Fexposition (1,119)=
79.881, pb0.001; Finteraction (5,119)=15.437, pb0.001] (Fig. 4A). The
pretreatment of mice with SCH 23390 (15 μg/kg, i.p.) was not able to
prevent the uliginosin B antinociceptive effect in hot-plate test
(Fig. 4B). Two-way RMANOVA revealed a signiﬁcant effect of treatment
[F (5,119)=2.736, pb0.05], exposition [F (1,119)=94.902, pb0.001]Fig. 4. Effect produced by pretreatment with naloxone (NAL — 2.5 mg/kg, s.c.) (panel
A), SCH 23390 (SCH — 0.015 mg/kg, i.p.) (panel B) and sulpiride (SULP — 10 mg/kg,
i.p.) (panel C) before uliginosin B treatment on the hot-plate in mice. Data are pres-
ented in mean±S.E.M. (n=10 mice/group). Signiﬁcantly different values were
detected by ANOVA two way RM followed by Student-Newmann–Keuls: ⁎⁎⁎pb0.001,
⁎⁎pb0.01, ⁎pb0.05 compared to vehicle; ###pb0.001 compared to their respective
basal latency (Basal).and interaction treatment×exposition [F (5,119)=9.052, pb0.001].
Uliginosin B alone or combined with SCH 23390 differs from vehicle
at second exposition and its basal responsiveness. The antinociceptive
effect of uliginosin B was completely prevented by pretreatment
with sulpiride (10 mg/kg, i.p.) as demonstrated in Fig. 5C. Two-
way RM ANOVA revealed a signiﬁcant antinociceptive effect only
when uliginosin B was administered alone [Ftreatment (5,119)=4.786,
pb0.001; Fexposition (1,119)=24.255, pb0.001; Finteraction (5,119)=
4.101, pb0.01].
Fig. 5 shows the effect of the antagonist pretreatments on the ataxic
effect of uliginosin B 90 mg/kg (i.p.) in the rotarod test. The pre-
treatment with naloxone (2.5 mg/kg, s.c.) abolished the motor impair-
ment induced by uliginosin B (Fig. 5A and B). Two-way RM ANOVA
analysis revealed that uliginosin B increased the number of falls
[Ftreatment (3,79)=20.844, pb0.001; Fexposition (1,79)=24.261,
pb0.001; Finteraction (3,79)=13.927, pb0.001] (Fig. 5A) and decreased
the permanence time [Ftreatment (3,79)=11.090, pb0.001; Fexposition
(1,79)=17.933, pb0.001; Finteraction (3,79)=6.460, pb0.001] (Fig. 5B)
only when it was administered alone. The pretreatment with SCH
23390 (15 μg/kg, i.p.) partially prevented the effect of uliginosin B in
reducing the number of falls [two-way RM ANOVA: Ftreatment (3,79)=
13.688, pb0.001; Fexposition (1,79)=24.747, pb0.001; Finteraction (3,79)=
11.213, pb0.001] (Fig. 5C) and increasing the permanence time [two-
way RM ANOVA: Ftreatment (3,79)=14.090, pb0.001; Fexposition (1,79)=
14.579, pb0.001; Finteraction (3,79)=6.239, pb0.002] (Fig. 5D) on
rotarod test.
The results depicted in the Fig. 5E and F show that the pre-
treatment with sulpiride (10 mg/kg, i.p.) partially prevented the atax-
ic effect of the uliginosin B in reducing the number of falls [two-way
RM ANOVA: Ftreatment (3,79)=13.637, pb0.001; Fexposition (1,79)=
28.328, pb0.001; Finteraction (3,79)=12.366, pb0.001]; the decrease
in the permanence time was also partially prevented by pretreatment
with sulpiride [two-way RM ANOVA: Ftreatment (3,79)=8.721,
pb0.001; Fexposition (1,79)=26.298, pb0.001; Finteraction (3,79)=
7.588, pb0.001].
Uliginosin B up to 10−5 M did not affect [3H]-naloxone, [3H]-SCH
23390 and [3H]-sulpiride binding to rat brain membrane preparations
as well as did not affect [35S]-GTPγS binding in striatum and thalamus
membranes (data not shown).
4. Discussion
The results from our study clearly demonstrate that uliginosin B
presents antinociceptive effect in mice when evaluated in acetic
acid induced writhing and hot-plate tests. The uliginosin B effect on
thermal nociception was dose-dependent and the maximal effect
was reached at doses that did not impair motor coordination
(15 mg/kg, i.p.; 90 mg/kg, p.o.). Thus, it is reasonable to assume that
this dimeric phloroglucinol contributes to the H. caprifoliatum and
H. polyanthemum antinociceptive effects previously reported by Haas
et al. (2010) and Viana et al. (2003).
Besides the antinociceptive effect, uliginosin B at the highest dose
(90 mg/kg, i.p.) presented an ataxic effect in the rotarod. Plummer
et al. (1991) support the validity of hot-plate test as antinociceptive
assay even in the presence of a substantial impairment of motor per-
formance. However, the rotarod impairment also could be indicative
of neurotoxicity, hypotension, muscle relaxation, sedation or catalepsy
(Le Bars et al., 2001). Some of these effects, such as hypotension and
sedation, could be at least in part consequence of dopaminergic or opi-
oid system activation (Lahlou, 1998; Pelissier et al., 2006; Spetea et al.,
2010).
The antinociceptive and ataxic effects seem to be mediated by
distinct receptors since the effect on the hot-plate was completely
abolished by naloxone (uliginosin B 15 mg/kg, i.p.) and sulpiride
(uliginosin B 15 mg/kg, i.p. and 90 mg/kg, i.p.) but it was unaffected
by SCH 23390. On the other hand, the impairment induced by
Fig. 5. Effect produced by pretreatment with naloxone (2.5 mg/kg, s.c.) (panel A and B), SCH 23390 (0.015 mg/kg, i.p.) (panel C and D) and sulpiride (10 mg/kg, i.p.) (panel E and F)
before uliginosin B (ULI — 90 mg/kg, i.p.) treatment in fall number and higher permanence time on rotarod test. Data are presented in mean±S.E.M. (n=10 mice/group). Signif-
icantly different values were detected by ANOVA two way RM followed by Student-Newmann–Keuls: ⁎⁎⁎pb0.001, ⁎⁎pb0.01 compared to vehicle; ###pb0.001, ##pb0.01 compared
to their respective basal time (Basal); aaapb0.001, apb0.05 compared to uliginosin B 90 mg/kg i.p.
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completely prevented by naloxone and partially prevented by sulpiride
and SCH 23390. Therefore, it is possible that the D1-like receptors are
implicated in the ataxic effects but do not account to the antinociceptive
effect whereas opioid and D2-like receptors activation appears to
underlie both effects. However, receptors activation seems to be indi-
rect in any case, given that we demonstrated that uliginosin B up to
10−5Mdoes not alter [35S]-GTPγS binding in the thalamus and striatum
membranes, nor affect [3H]-naloxone, [3H]-SCH 23390 and [3H]-
sulpiride binding in rat forebrain and striata membranes.
The uliginosin B action on the dopaminergic neurotransmission is in
agreement with the dopaminergic activity of H. caprifoliatum and its
main phloroglucinol derivative described by Viana et al. (2005, 2006).
Moreover, recently Stein et al. (2012) demonstrated that uliginosin B
inhibits monoamines synaptosomal reuptake in rat brain, especially
dopamine. Thus, probably the compound stimulates the dopaminergic
neurotransmission by increasing dopamine levels in synaptic cleft
with consequent activation of dopamine receptors. A similar pharmaco-
logical proﬁle was also demonstrated for hyperforin, which presents
non-speciﬁc pre-synaptic effects resulting fromnon-selective inhibition
of the uptake of several neurotransmitters and indirect interactionwith
dopamine and opioid receptors (Mennini and Gobbi, 2004). The
antidepressant-like activity of hyperforin was completely antagonized
by BD 1047— selective σ1 antagonist (Cervo et al., 2005). Furthermore,hyperforin inhibits rat bladder contractility in vitro, at least in part, by
opioid receptors activation (Capasso et al., 2004).
The antinociceptive mechanism of action of antidepressant com-
pounds has been matter of discussion (Densmore et al., 2010; Ripoll
et al., 2006; Yasuda et al., 2005). The antinociceptive effect of serotonin/
noradrenaline reuptake inhibitors enhanced when they were combined
with dopamine reuptake inhibitors (Pedersen et al., 2005) or direct D2
receptor agonist— quinpirole (Munro, 2007). Gray et al. (1998) showed
that opioid antagonists reduce the antinociceptive potency of several
antidepressants and suggested that antidepressantsmay induce endoge-
nous opioid peptide release.
Millan (2002) and Wood (2008) demonstrated that the activation
of dopaminergic neurotransmission, particularly through D2-like re-
ceptor, induces antinociceptive effects. Dopaminergic autoreceptor
antagonists and agonists have been proposed to develop drugs for
treating pain (Wood, 2008). For instance, apomorphine – dopaminergic
agonist – showed antinociceptive effect which is blockaded by central
D2 antagonists, but not by peripheral D2 antagonists (Pelissier et al.,
2006); amisulpiride and levosulpiride have antinociceptive effect by
acting as an antagonist of D2/D3 dopaminergic receptors, with selective
preference for presynaptic autoreceptor (Weizman et al., 2003).
It is known that the mesolimbic dopaminergic pathway activation
stimulates the release of endogenous opioid peptides (Soderman and
Unterwald, 2009) what could explain the opioid effect of uliginosin B.
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modulation and nociception has been discussed by several authors:
dopaminergic receptor antagonists attenuate nociception induced
by morphine in ventral tegmental area (Altier and Stewart, 1998);
systemic administration of morphine alters dopamine spinal levels
(Weilfugazza and Godefroy, 1991) and this raise was not inﬂuenced
by dopaminergic antagonists (Millan, 2002); depletion of the gene
encoding D2 receptors or administration of an antisense probe direct-
ed against D2 receptors potentiated antinociception elicited by μ and
κ-opioid agonists (King et al., 2001); D2 agonists enhance opioid
antinociception (Kamei and Saitoh, 1996; Millan, 2002; Zarrindast
et al., 1999).
Furthermore, Altier and Stewart (1993, 1996) demonstrated that
the ventral tegmental area is associated with opioid and dopaminergic
nociception and Ambrose and co-workers suggested the co-existence
between opioid and dopaminergic receptors in striatal neurons
(Ambrose et al., 2004, 2006). Dorsolateral striatum D2 receptors, but
not D1, are involved in the modulation of persistent nociception
(Magnusson and Fisher, 2000). The activation of some dopaminergic
neurons from other structures such as periaqueductal gray also pro-
vokes antinociceptive effects as well as modulates the antinociceptive
effect of morphine (Meyer et al., 2009). Tramadol and tapentadol, effec-
tively used to treat pain, acts as μ-opioid receptor agonist and mono-
amine reuptake inhibitors (Guay, 2009).
The ataxic effect produced by uliginosin B 90 mg/kg, i.p. seems to be
dependent on activation of opioid, dopaminergic D1-like and D2-like
receptors. It is well accepted that dopaminergic neurotransmitter
system plays a role in the motor system. However, data about speciﬁc
subtype of dopamine receptors are limited. Spinal application of dopa-
minergic agonists elicits a pronounced hypotension and bradycardia,
which affect rotarod test, probably via activation of D2 receptors
(Lahlou, 1998; Pellissier and Demenge, 1991). Animals with D1-like
receptors inhibition presented a poor performance on the rotarod
(Voller et al., 2008).
Effects of opioid agonists on motor coordination have been also
reported. The systemic administration of morphine caused dose-
dependent suppressive effects on motor coordination linked to the
μ-opioid receptor activation in the basal ganglia, nucleus raphe pontis,
periaqueductal gray and locus coeruleus (Spetea et al., 2010).
In conclusion, uliginosin B induced antinociceptive and ataxic
effects in mice depending on the dose and/or route tested. It seems
that the D1-like receptors are implicated in the ataxic effects but
does not account notably to the antinociceptive effect whereas opioid
and D2-like receptors activation appears to underlie both effects.
However receptors activation seems to be indirect since uliginosin B
does not bind to these receptors neither activates proteins G coupled
to them. Its effect could be, at least in part, related to its ability to inhibit
monoamine reuptake previously reported. Finally, the observation of
apparent conﬂicting results between in vivo and in vitro assays could
indicate eventual uliginosin B active metabolites. Our results suggest
that uliginosin B presents good bioavailability, since it was anti-
nociceptive by oral and intraperitoneal routes. On the other hand, the
ataxic effect was observed when uliginosin B was administered by
intraperitoneal route only suggesting that uliginosin B is somewhat
metabolized when administered orally, reducing ataxic effect. This
assumption deserves future studies because phloroglucinol derivatives,
such as uliginosin B, could represent novel chemical entities with dopa-
minergic and opioid action.Acknowledgments
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